Abstract 686: Subsequent invasive breast cancer risk after DCIS treatment in multinational PRECISION consortium cohorts comprising 48,576 patients
Renée Schmitz(The Netherlands Cancer Institute), Marjanka K. Schmidt(University of Cambridge), Yat-Hee Liu(The Netherlands Cancer Institute), Michael Schaapveld(The Netherlands Cancer Institute), Danalyn Byng(Duke University), Jelle Wesseling(Leiden University Medical Center), Alastair M. Thompson(King's College - North Carolina), Jasmine Timbres(King's College London), Alexandra W. van den Belt‐Dusebout(The Netherlands Cancer Institute), Terry Hyslop(Duke Cancer Institute), Brian A. Menegaz(Baylor College of Medicine), Elinor J. Sawyer(King's College London), Karen Clements(National Health Service), Esther H. Lips(Leiden University Medical Center), Thomas Lynch(Duke University), Deborah Collyar(Advocates for Youth), Chiara Cresta(The Netherlands Cancer Institute), Yi Ren(Duke University), Shelley Hwang(Duke University), Marc D. Ryser(University of Bern)
Cited by 0
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716
MicroRNA Related Polymorphisms and Breast Cancer Risk
|PLoS ONE|2014|638